Dr. Rafael Gonzales
The use of Stem and Progenitor Cells for Drug Discovery and Development
Dr. Gonzalez received his B.S. in Biological Science and his Ph.D. in Anatomy and Neurobiology from the University of California, Irvine, CA. During his Ph.D., he lead pre-clinical studies that precipitated the start-up of Ability Biomedical, a company since acquired by Bristol-Myers Squibb, that developed an anti-IP10 antibody to treat several degenerative disorders such as multiple sclerosis, rheumatoid arthritis, and spinal cord injury. Dr. Gonzalez also was involved with preclinical studies aimed at using human embryonic stem cells to treat spinal cord injury. Prior to joining DaVinci Biosciences, Dr. Gonzalez served as a Research Scientist at PrimeGen Biotech where he was responsible for experiments involving adult and pre-natal stem cells for potential clinical application, and for developing PrimeGen's pre-clinical stem cell/spinal cord injury model. In his current position as the VP of Research & Development at DaVinci Biosciences, Dr Gonzalez is responsible for the development of clinical stem cell applications for several disease/trauma states. In addition to his expertise in degenerative disorders involving the spinal cord, he has extensive experience in stem cell culture and biology from human embryonic, pre-natal and adult sources.